本帖最后由 老马 于 2013-3-13 13:43 编辑 6 n& B' ]- u3 q, H+ Z
9 b7 ]* v) J+ B% J0 t3 R
健择（吉西他滨）+顺铂+阿瓦斯汀
4 Y" E6 p$ y% J# ` Gemzar +Cisplatin + Avastin
7 M [2 M& |; r( W8 q2 [8 ]http://annonc.oxfordjournals.org/content/21/9/1804.full+ ], W8 e4 j) i7 r4 o
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 L4 V: k* ^0 C. h. q: k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% {( g" w/ O2 c6 `- n# hResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 1 d* [6 v9 {* w; R, t! z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 846)
1 d1 L0 s" `) P5 k0 r* U, \
华为网盘附件：
! |# N. x' ]% v% r7 ~ U【华为网盘】ava.JPG
, z$ M" Y$ v9 U. |% C- v" X |
显身卡
